<i>In vitro</i> Characterization of SARS-CoV-2 Protein Translated from the Moderna mRNA-1273 Vaccine

Veenstra, Timothy D.; Injeti, Elisha R.; Pauley, Bradley

doi:10.1101/2022.03.01.22271618

Cited by 4 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it has not been peer reviewed, a study by Veenstra et al (2022) addresses this astounding regulatory disaster, over a year after billions of doses had been injected into arms. As the authors write, there has been "extensive research around mRNA vaccines and their proposed utility…but none describe the characteristics of the full-length protein obtained from the modified/synthetic mRNA that is part of the Moderna and Pfizer-BioNTech vaccines.…”

Section: "Autoimmune" Political Attacks On Regulation and Quality Con...mentioning

confidence: 99%

The COVID Emergency as Autoimmune Disease

Gundermann

2024

Catalyst

View full text Add to dashboard Cite

This article analyzes the United States biosecurity state’s orchestration of the COVID-19 phenomenon into a public health emergency, tracing the legal platforms that made this mobilization possible. Leaning on the longstanding reverberations between political and biological discourses around immunology, I argue that the polis entered into a state of autoimmune disease where its public/private biosecurity organisms attacked its own body politic. COVID-19 constitutes the culmination of a development that had been in the making for several decades. Besides parsing the central legislative inventions that form the basis of this operation, the article analyzes the most central medical countermeasure deployed as the ostensible remedy to the public health emergency. A novel technological platform (mRNA transfection) is introduced as the solution to the threat of infection (falsely promising immunity). This platform is equally built on autoimmune logic, not traditional immunity. Unlike previous vaccine technologies, synthetic mRNA transfections coerce the body’s cells to produce the antigen against which the immune reaction is mounted. The immune system will then attack those cells that express the antigen, the most publicly acknowledged example being myocarditis. The feedback loop between biological and political discourses on autoimmune disease has begun to restructure societies globally.

show abstract

Section: "Autoimmune" Political Attacks On Regulation and Quality Con...mentioning

confidence: 99%

The COVID Emergency as Autoimmune Disease

Gundermann

2024

Catalyst

View full text Add to dashboard Cite

show abstract

“…Another consideration could be the size of the protein that needs to be coded by mRNA. Full S spike protein coded by the mRNA vaccines is about 180 kDa, whereas the mRNAs used in protein replacement therapy so far code for proteins in the range of 27–127 kDa as seen in Table 1 [ 139 , 140 ]. Should the need arise for longer mRNAs, delivery vector design can be revisited to be able to accommodate bigger constructs and deliver them efficiently.…”

Section: Conclusion and Future Applicationsmentioning

confidence: 99%

mRNA in the Context of Protein Replacement Therapy

et al. 2023

View full text Add to dashboard Cite

Protein replacement therapy is an umbrella term used for medical treatments that aim to substitute or replenish specific protein deficiencies that result either from the protein being absent or non-functional due to mutations in affected patients. Traditionally, such an approach requires a well characterized but arduous and expensive protein production procedure that employs in vitro expression and translation of the pharmaceutical protein in host cells, followed by extensive purification steps. In the wake of the SARS-CoV-2 pandemic, mRNA-based pharmaceuticals were recruited to achieve rapid in vivo production of antigens, proving that the in vivo translation of exogenously administered mRNA is nowadays a viable therapeutic option. In addition, the urgency of the situation and worldwide demand for mRNA-based medicine has led to an evolution in relevant technologies, such as in vitro transcription and nanolipid carriers. In this review, we present preclinical and clinical applications of mRNA as a tool for protein replacement therapy, alongside with information pertaining to the manufacture of modified mRNA through in vitro transcription, carriers employed for its intracellular delivery and critical quality attributes pertaining to the finished product.

show abstract

“…SARS-CoV-2 is one of the Beta coronavirus strains which was identified in Wuhan, China in December 2019 for the first time (1)(2)(3) . After entering the body, SARS-CoV-2 binds to its receptor via the 180-KD spike protein (4)(5)(6). The studies showed that the angiotensinconverting enzyme-2 (ACE-2) on host cells acts as a high-affinity receptor for SARS-CoV-2 (7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of anti-spike glycoprotein antibody and neutralizing antibody response of different vaccine platforms. A protocol of systematic review and meta-analysis of COVID-19 vaccine clinical trial studies

Mirzakhani

Tahmasebi

Dashti

et al. 2022

Preprint

View full text Add to dashboard Cite

BackgroundThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. SARS-CoV-2 transmit among the people fast and infected thousands of people daily around the world. Because of rapid transmission of SARS-CoV-2 among the people, there is an urgent need to prevent people from infection or hospitalization and control the disease.MethodsWe will search electronic databases such as PubMed, Web of Science, Cochrane (CENTRAL), Scopus, Google scholar, the key journals (vaccine and vaccines). Moreover, trial registry including clinicalTrials.gov, WHO ICTRP, and ISRCTN will be searched. We will only select all clinical trial studies in any phases of evaluation (i.e. phase I, II, II, IV). For anti-spike glycoprotein antibody (IgG) response and neutralizing antibody response, we will report Ratio of Geometric Mean (RoGM), Ratio of Mean (RoM) or standardized mean difference (SMD) depends on type of articles.DiscussionVarious vaccine platforms have been developed to increase the resistance to the SARS-CoV2 virus and reduce hospitalization and mortality rates. The comprehensive data gathering and analysis of results will guide scientists about the best available evidence. Moreover, the current study results may indicate which of the vaccine platforms are more effective and safe for COVID-19.

show abstract

In vitro Characterization of SARS-CoV-2 Protein Translated from the Moderna mRNA-1273 Vaccine

Cited by 4 publications

References 10 publications

The COVID Emergency as Autoimmune Disease

The COVID Emergency as Autoimmune Disease

mRNA in the Context of Protein Replacement Therapy

Evaluation of anti-spike glycoprotein antibody and neutralizing antibody response of different vaccine platforms. A protocol of systematic review and meta-analysis of COVID-19 vaccine clinical trial studies

Contact Info

Product

Resources

About